Estrogen receptor mutation: a new strategy to overcome endocrine resistance
Andrea Moretti(Arcispedale Sant'Anna), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Patrizia Querzoli(University of Ferrara), I. Toma(Arcispedale Sant'Anna), Laura Lupini(University of Ferrara), F. Daniel(Aberdeen Royal Infirmary), Eri Banno(Arcispedale Sant'Anna), Lucia Da Ros(University of Ferrara), Lorenzo Belluomini(University of Ferrara), Luca Martella(Arcispedale Sant'Anna), Federica Lancia(University of Ferrara), Massimo Negrini(University of Ferrara), I. Carandina(Arcispedale Sant'Anna), C. Nisi(Arcispedale Sant'Anna), Cristian Bassi(University of Ferrara)
Cited by 1
Related Papers
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
|Annals of Oncology|2012|339
Isolation and characterization of CD146+ multipotent mesenchymal stromal cells
|Experimental Hematology|2008|254
Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy
|Cancer Research|2010|244
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240